

Original Research Article

Evaluation of Iron Profiles and Coagulation Profiles in Ischemic Heart Diseases Patients in Elmek Nimir Hospital, Sudan

Hind Mohammed Ali¹, Hamza Ahmed Hassan¹, Ghanem Mohammed Mahjaf², Tibyan Abd Almajed³, Wafaa Bashir Haj Ahmed¹, Mosab Nouraldein Mohammed Hamad^{4*}

¹Department of Haematology, Faculty of Medical Laboratory Sciences, Shendi University, Sudan

²Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Shendi University, Sudan

³Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, Shendi University, Sudan

⁴Assistant Professor, Microbiology Department, Faculty of Medicine, Elsheikh Abdallah Elbadri University, Sudan

*Corresponding Author: Mosab Nouraldein Mohammed Hamad

Assistant Professor, Microbiology Department, Faculty of Medicine, Elsheikh Abdallah Elbadri University, Sudan

Article History: | Received: 26.11.2023 | Accepted: 01.01.2024 | Published: 03.01.2024 |

Abstract: Background: Ischemic heart disease (IHD) is a constellation of diseases that includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It belongs to the group of cardiovascular diseases and is the most common type among them. Iron is an essential trace element. It plays an important role in maintaining various cellular functions and enzymatic reactions. On the other hand, excessive intake of iron is known to be a risk factor for the progression of atherosclerosis. Abnormal iron deposition in the heart causes hemochromatosis and dilated cardiomyopathy, which leads to ischemic heart disease. **Objective:** This study aims to investigate the role of serum iron, serum ferritin, total iron-binding capacity (TIBC), PT, and PTT in ischemic heart disease (IHD) and their relationship with other risk factors for IHD. **Methods:** This is a prospective, case-control, cross-sectional analytical study conducted at Elmek Nimir University Hospital, Shendi City, to assess the iron profile and coagulation profile of patients with ischemic heart disease. The study included (30) patients diagnosed with ischemic heart disease and the study group was compared with the mean of the control group (20). Serum iron, ferritin, and TIBC were estimated using a spectrophotometer, and PT and PTT were estimated using manual methods. Data were collected using a structured personal questionnaire and the program (SPSS) version (11.5) was used for data analysis. **Results:** In this study, patients with ischemic heart disease were (40%) male and (60%) female. In this study, iron averaged (41.0) ug/dl (*P. value* 0.010), ferritin averaged (233.0) ug/dl (*P. value* 0.000), and TIBC averaged (44.0) µg/dl. Was shown. (*P. value* 0.000) compared to mean controls (27.0), (162.0), (56.0). A significant difference was found between the iron profile and his IHD. This study showed the mean PT, PTT for cases (13.4), (40.4) (*P-value* 0.024), (*P. value* 0.009) compared with the mean for controls (12.0), (35.1). A significant difference was found between the coagulation profile and IHD. **Conclusions:** This study concluded that serum levels of iron, ferritin, TIBC, PT, and PTT may be associated with Ischemic heart disease.

Keywords: Ischemic Heart Disease, Iron, Ferritin, PT, PTT, Shendi, Sudan.

Copyright © 2024 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Cardiovascular disease (CVD) is a type of disease that affects the heart, blood vessels (arteries, capillaries, veins), or both [1]. Cardiovascular disease refers to all diseases that affect the cardiovascular system, primarily heart disease, cerebral and renal vascular disease, and peripheral arterial disease [2]. The causes of cardiovascular disease are varied, but

atherosclerosis and/or hypertension are the most common [3]. In addition, a variety of physiological and biochemical changes alter cardiovascular function in association with aging, leading to an increased risk of subsequent cardiovascular disease, even in healthy asymptomatic individuals [4]. Cardiovascular disease is a leading cause of death. In 2008, 30% (30%) of all deaths worldwide were due to cardiovascular disease. Mortality from cardiovascular disease is also higher in

Citation: Hind Mohammed Ali *et al* (2024). Evaluation of Iron Profiles and Coagulation Profiles in Ischemic Heart Diseases Patients in Elmek Nimir Hospital, Sudan. *SAR J Pathol Microbiol*, 5(1), 8-12.

low- and middle-income countries, as more than 80% of all cardiovascular deaths occur in these countries [5]. It is also estimated that by 2030 more than 23 million people will die annually from cardiovascular disease [5, 6]. The causes, diagnosis, prevention, control, and/or treatment of all forms of the cardiovascular disease continue to be an active area of biomedical research, with hundreds of scientific studies published each week. I'm here. In 2013, coronary heart disease (CHD) was the leading cause of death worldwide, with (8.14) million deaths (16.8%) compared with (5.74) million deaths (12%) in 1990 [7]. The risk of dying from (CAD) at a given age decreased between 1980 and 2010, especially in developed countries [8]. The number of cases of (CAD) in a given age group also decreased between 1990 and 2010 [9]. In the United States in 2010, approximately (20%) of (ages 65+) had (CAD) (CAD), while (7%) and (1.3%) (Ages 45–64) (CAD) of (18-45 years old) Now. (10) More men than women at a given age [10]. The Sudan Household Survey (SHHS) reported a prevalence of heart disease (2.5%). Hypertensive heart disease (HHD), rheumatic heart disease (RHD), ischemic heart disease (IHD), and cardiomyopathy account for more than (80%) of (CVD) in Sudan [6].

Heart disease is the leading cause of morbidity and mortality in Sudan. Hypertension (RHD), (IHD), and cardiomyopathy account for the majority of four (CVD). Hypertension is common and poorly controlled [11]. Most cardiovascular diseases can be prevented by addressing risk factors such as tobacco use, unhealthy diet and obesity, physical inactivity, hypertension, diabetes, and elevated lipids. More than half of the heart disease deaths in 2009 were men. Coronary heart disease (CHD) is the most common type of heart disease, causing more than (385,000) deaths each year [6]. Ischemic heart disease is associated with progressive mechanical obstruction, dynamic obstruction, plaque inflammation, instability, and rupture, followed by superimposed thrombosis. Clinicians are employing additional tools to aid clinical assessment and improve their ability to identify "at-risk" patients who are at risk for cardiovascular disease [12, 13]. Biomarkers are one of the tools to better identify at-risk individuals, diagnose medical conditions quickly and accurately, and effectively diagnose and treat sick patients. Biomarkers can be measured in biological samples (as blood, urine, or tissue tests), can be human records (blood pressure, electrocardiogram, or holder), or imaging tests (echocardiogram). Normally, very small amounts of iron are present in most body cells, plasma, and other extracellular fluids, and the body strictly limits its iron supply so that every day (0.1%) of the body's iron content is lost. maintain. Mainly in desquamated cells [14].

Iron's high activity is a two-edged sword, and free iron ions in the body also participate in destructive chemistry, primarily in catalyzing the formation of toxic free radicals. Iron play role in the process of atherosclerosis by catalyzing the formation of free

radical and also this contributes to reperfusion damage. High serum ferritin concentration was associated with increased risk of myocardial infarction, independent of major cardiovascular risk factors. Abnormal deposition of iron in the heart cause hemochromatosis and dilated cardiomyopathy and this causes causing ischemic heart disease [1]. Coagulation play role in ischemic heart disease, increase plasma levels of coagulation protein are associated with an increased risk of myocardial infarction The prothrombin time alone is derived from measures of prothrombin ratio {PR} and international normalized ratio {INR} are assays evaluating the extrinsic pathway and common pathway of coagulation. They are used to determine the clotting tendency of blood in the measure of warfarin dosage [2]. The role of blood clotting activation such as elevated circulating level of a marker of thrombin generation and fibrin peptide A in the occurrence of angina in ischemic heart disease [3]. Activated thromboplastin time is used to monitor the effects of heparin on intrinsic pathways and detect defects in factors XII, XI, IX, VIII, and the common pathway.

MATERIAL AND METHOD

Study Design

This is an analytical, laboratory-based, hospital case-control study to evaluate the iron profile and coagulation profile of patients with ischemic heart disease at Elmek-Nimir University Hospital for the period from December 2021 to October 2021.

Study Area

The study was conducted at his Elmek-Nimir University Hospital in Shendi City, Sudan. Shendi is a city in northern Sudan, northeast of Khartoum, on the eastern bank of the Nile River (150 km). Shendi is also about (45 km) southwest of the ancient city of Meroe. Located on the Nile state River. Its main western bank suburb is Almatama. A major traditional trade route through the Bayuda Desert connects Al Matamma to the northwest with Napata (250 km) in Malawi.

Study Population: A total of (50) samples were collected from the study group of ischemic heart patients.

Inclusion Criteria: Both men and women with ischemic heart disease (medicated or not) participated in the study.

Data Collection Tools

Data were collected using a laboratory-based scored pre-coded questionnaire. Its nature is designed to ultimately retrieve useful information for research.

Ethical Considerations

The procedure for venous blood sampling was explained to the patient undergoing the examination. All participants were briefed on the purpose and procedures of the study during the interview period. Valid written consent was obtained from all participants. All results were highly private and confidential

RESULT

Demographically, a total of 30 blood samples were collected from patients with ischemic heart disease and 20 from healthy subjects as controls. Participation in ischemic heart disease mirrored 30 (60%) and 20 (40%) of the control group (Table1). The frequency of ischemic heart disease patients was 9 males (18%) and 21 females (42%) (Table2). As a result of the analysis, the mean PT and PTT of the case group (13.4 seconds) (and 40.4 seconds) was), and the mean of PT and PTT of the

control group was (12.0 seconds) (and 35.1 seconds) (Table 3). The analysis also shows the average iron, TIBC, and ferritin values (41.0 ng/dl) in this case. (44.0), (233.0), and mean iron and TIBC and ferritin in controls (27.0 ng/dl), (56.0), (162, 0) (Table 4). The male and female averages in PT were (13.3), (13.5) seconds, and the male and female averages in PTT were (43.6) (39.0) seconds (Table 5). Also, the mean of S. iron, TIBC, S. Ferritin in men (38.0), (45.0), (255.0) and the mean of S. iron, TIBC, S. Ferritin in women (42,2), (56.0), (224.2) (Table 6).

Table 1: Distribution of the Study Population After Testing and Controls

<i>Variables</i>	<i>Frequency</i>	<i>Percent</i>
<i>Test</i>	30	60%
<i>Control</i>	20	40%
Total	50	100%

Table 2: Distribution of Study According to Sex

<i>Sex</i>	<i>Frequency</i>	<i>Percent</i>
<i>Male</i>	9	30%
<i>Female</i>	21	70%
Total	30	100%

Table 3: Comparison between Case and Control in PT and PTT

<i>Group</i>	<i>N</i>	<i>Mean</i>	<i>SD</i>	<i>P. value</i>
PT	<i>Case</i>	30	13.4	0.024
	<i>Control</i>	20	12.0	
PTT	<i>Case</i>	30	40.4	0.009
	<i>Control</i>	20	35.1	

Table 4: The Comparison between Iron and TIBC and Ferritin in Case and Control

<i>Group</i>	<i>N</i>	<i>Mean</i>	<i>SD</i>	<i>P. value</i>
Iron	<i>Case</i>	30	41.0	0.010
	<i>Control</i>	20	27.0	
TIBC	<i>Case</i>	30	44.0	0.000
	<i>Control</i>	20	56.0	
Ferritin	<i>Case</i>	30	233.0	0.000
	<i>Control</i>	20	162.0	

Table 5: Comparison between PT and PTT in Male and Female

<i>Group</i>	<i>N</i>	<i>Mean</i>	<i>SD</i>	<i>P. value</i>
PT	<i>Male</i>	9	13.3	0.874
	<i>Female</i>	21	13.5	
PTT	<i>Male</i>	9	43.6	0.135
	<i>Female</i>	21	39.0	

Table 6: The Comparison between Iron and TIBC and Ferritin in Male and Female

<i>Group</i>	<i>N</i>	<i>Mean</i>	<i>SD</i>	<i>P. value</i>
Iron	<i>Male</i>	9	38.0	0.456
	<i>Female</i>	21	42.2	
TIBC	<i>Male</i>	9	45.5	0.416
	<i>Female</i>	21	56.0	
Ferritin	<i>Male</i>	9	255.0	0.000
	<i>Female</i>	21	224.2	

DISCUSSION

Ischemic heart disease (IHD) is a constellation of diseases that includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death [15]. Studies have shown that female patients are infected more often than male patients. Results of the presented study showed a significant increase in PT and PTT compared to controls (*P. value* 0.024) and PTT (0.009). The results of this current study are consistent when compared to a study performed by Haseeb Akhan that showed changes in prothrombin time and activated partial thromboplastin time in patients with acute myocardial infarction. As a result, the average S. The iron content of the case (41.0 µg/dl) and the control (27.0 µg/dl) showed a significant difference (*P. value* 0.010). The results also show that the mean of TIBC was in cases (44.0 µg/dl) and controls. (56.0 µg/dl), and this result showed significant variation (*P. value* 0.000). On the other hand, the dominant result was that the mean ferritin values showed significant static values (*P. value* 0.000) in cases (233.0 µg/dl) and controls (162.0 µg/dl). This study was consistent with that by Das De *et al.*, A 2015 study showed a significant association between markers of iron status and IHD. Furthermore, this study was consistent with that reported by Suuny Chopra *et al.*, A 2015 study confirmed that an IHD patient experienced a significant increase in his S. iron and ferritin and a significant decrease in his TIBC [16]. Furthermore, the results showed that the average PT was in males (13.3 s) and females (13.5 s). On the other hand, the results show the average PTT values for men (43.6 seconds) and women (39.0 seconds), with no significant difference between men and women. The results of this study showed significant statistical differences between PT and PTT compared by gender. Further results were iron and TIBC in men (38.0), (45.5) and women (42.2), (56.0). These results indicated no significant difference between males and females (*P. value* 0.456). On the other hand, the average value of S. ferritin was (255.0) in men and (244.2) in women. These results showed a significant difference between men and women (*P. value* 0.000), this study disagreed with that reported by wafaa Bashir and her colleague, 2022 showed that the mean of S. ferritin in males was (206.3µg/dl) and in females was (162.2µg/dl) which showed an insignificant statically value, (*P. value* 0.101) [17].

CONCLUSION

PT and PTT were increased in subjects with ischemic heart disease compared to control subjects. S. iron and S. ferritin were increased in ischemic heart disease patients compared to healthy controls. TIBC was lower in the ischemic heart disease patient compared to healthy subjects in the control group. PT and PTT increase according to gender. S. iron, TIBC, s. Ferritin increased according to gender.

Sources of Funding: There was no specific grant for this research from any funding organization in the public, private, or nonprofit sectors.

Conflict of Interest: The author has affirmed that there are no conflicting interests.

REFERENCES

1. Maton, A. (1993). Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D.Wright. *Human Biology and Health*. Englewood Cliffs, New Jersey: Prentice Hall, ISBN 0-13-981176-1.
2. Bridget, B., & Kelly, (2010). Institute of Medicine; Fuster, Valentin. Promoting Cardiovascular Health in the Developing World: *A Critical Challenge to Achieve Global Health*. Washington, D.C: National Academies Press, ISBN 0-309-14774-3.
3. Onow, R. O. (2012). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa. *Saunders Elsevier*, 2012.
4. Dantas, A. P., Jiménez-Altayó, F., & Vila, E. (2012). Vascular aging: facts and factors. *Frontiers in physiology*, 3, 325. doi:10.3389/fphys.2012.00325. PMID 22934073.
5. Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. *PLoS medicine*, 3(11), e442.
6. Peden, M., Scurfield, R., Sleet, D., Mohan, D., Hyder, A. H., & Jarawan, E. (2010). World report on road traffic injury prevention. Geneva: World Health Organization. www.who.int/world-healthday/2004/infomaterials/world_report/en/html Date of access: 22 Sept. 2010.
7. Finegold, J. A., Asaria, P., & Francis, D. P. (2013). Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. *International journal of cardiology*, 168(2), 934-945. doi:10.1016/j.ijcard.2012.10.046. PMID 23218570.
8. Hung, M. J., & Cherg, W. J. (2003). Comparison of white blood cell counts in acute myocardial infarction patients with significant versus insignificant coronary artery disease. *American Journal of Cardiology*, 91(11), 1339-1342.
9. Moran, A. E., Forouzanfar, M. H., Rotti, G. A., & Mensah. (2014). The global burden of disease 2010 study, doi:10.1161/PMID24573352.
10. Mozaffarian, D., Roger, V. L., Benjamin, E. J., & Berry. (2013). Heart disease and stroke statistics. *A report from the American heart association*, doi:10.1161/pmc:5408511/pmid:23239837.
11. Mendis, S., Puska, P., Norrving, B. E., & World Health Organization. (2011). *Global atlas on cardiovascular disease prevention and control*. World Health Organization.
12. Finks, S. W., Airee, A., Chow, S. L., Macaulay, T. E., Moranville, M. P., Rogers, K. C., & Trujillo, T. C. (2012). Key articles of dietary interventions that influence cardiovascular mortality. *Pharmacotherapy*:

- The Journal of Human Pharmacology and Drug Therapy*, 32(4), e54-e87. doi:10.1002/j.1875-9114.2011.01087.x. PMID 22392596.
13. Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., ... & Lisheng, L. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *The lancet*, 364(9438), 937-952.
 14. Burtis, C. E., Ashwood, E., & Bruns, D. E. (2006). Tietz text book of clinical chemistry and molecular diagnosis. Fourth edition. *United States of America*, 1186, 1192.
 15. Wong, N. D. (2014). Epidemiological studies of CHD and the evolution of preventive cardiology. *Nature Reviews Cardiology*, 11(5), 276-289. Doi:10.1038/nrcardio.2014.26. PMID 24663092.
 16. Chopra, S., Lal, A. K., Huria, A., & Dhar, M. (2015). Relationship between body iron status and cardiovascular risk factors in patients with coronary artery disease. *Journal of Cardiovascular Disease Research*, 6(1), 18.
 17. Ahmed, W. B. H., Abdalla, R. E., Mahjaf, G. M., Hassan, H. A., Mohamed, T. M. A., & Hamad, M. N. M. (2022). Evaluation of Iron Profile among Ischemic Heart Disease Patients in Shendi City, Sudan.